Meeting
2016 ASCO Annual Meeting
Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
Authors
Nina Niu Sanford
Harvard Radiation Oncology Program, Boston, MA
Nina Niu Sanford , Ming-Hui Chen , Marian J. Loffredo , Andrew A. Renshaw , Philip W. Kantoff , Anthony Victor D'Amico
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT00116220
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5070)
DOI
10.1200/JCO.2016.34.15_suppl.5070
Abstract #
5070
Poster Bd #
327
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Cardiovascular comorbidities in German prostate cancer patients under androgen deprivation therapy: Results from a retrospective analysis of patient data in urological outpatient centers.
First Author: Andreas Eisenhardt
Poster
2014 ASCO Annual Meeting
Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer: Toward a risk adapted approach for ADT use.
First Author: Lior Zvi Braunstein
Poster
2018 Cancer Survivorship Symposium
Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).
First Author: Ashley Hanlon
Poster
2018 Genitourinary Cancers Symposium
Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.
First Author: Brandon Arvin Virgil Mahal